ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2430

Antibodies To Porphyromonas Gingivalis as An Etiological Clue To The Development Of Anti-Citrullinated Protein Antibody Positive Rheumatoid Arthritis

Nastya Kharlamova1, Natalia Sherina1, Anne-Marie Quirke2, Kaja Eriksson3, Lena Israelsson4, Jan Potempa5, Patrick Venables6, Tulay Yucel-Lindberg3 and Karin Lundberg7, 1Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 2University of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom, 3Department of Dentistry, Karolinska Institutet, Stockholm, Sweden, 4Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 5Microbiology Department, Jagiellonian University, Krakow, Poland, 6Kennedy Institute of Rheumatology, Oxford, United Kingdom, 7Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: ACPA, antibodies and rheumatoid arthritis (RA), P. Gingivalis

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis: Human Etiology and Pathogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis (RA) is characterized by the production of autoantibodies to citrullinated proteins (ACPA). Citrullinated proteins are generated by the actions of peptidyl arginine deminase (PAD) enzymes during inflammation. Since ACPA can be detected prior to joint symptoms develop, it has been suggested that citrullination and break of tolerance to citrullinated proteins may be triggered outside the joint, potentially at mucosal surfaces. We hypothesize that Porphyromonas gingivalis, a major cause of chronic periodontitis (PD) and the only known pathogen to express PAD (P.PAD), is etiologically involved in the development of ACPA+ RA. We (Quirke, Potempa and Venables) have recently shown that autocitrullinated P.PAD is targeted by antibodies in RA, while arginine gingipain (another P. gingivalis-specific protein) is not. We have now investigated these antibody responses in more detail, with an aim to develop a serological test for diagnosing PD and to elucidate the potential link between PD and RA.

Methods: In-house ELISA assays, based on five different citrullinated P.PAD peptides (CPP3, 5, 6, 8 and 10), one arginine-containing control peptide (RPP3) and recombinant arginine gingipain protein (RgpB) were used to examine IgG responses in serum from: 102 ACPA+ RA cases; 98 ACPA- RA cases; 100 non-RA controls; 66 patients with confirmed PD; and 60 non-PD controls (confirmed by dentist). Mann-Whitney U-test for independent groups was used to determine statistical differences.

Results: The anti-CPP3 IgG response associated only, strongly and significantly with ACPA+ RA, while no antibody response was recorded towards RPP3. Also anti-CPP6 and 8 IgG showed similar association with ACPA+ RA, while the anti-CPP5 response also associated with confirmed PD (fig 1A). No anti-CPP10 IgG response could be detected in any subgroup. The antibody response towards RgpB associated mainly and significantly with confirmed PD. Compared to non-PD controls, anti-RgpB IgG levels were also increased in ACPA+ RA, ACPA- RA and non-RA controls, although no statistical significance could be detected between the groups (fig 1B).

Conclusion: Based on these results, anti-RgpB IgG could potentially be used as a serological marker to identify PD-cases retrospectively. This would be of great help when investigating the etiological link between PD and RA, or PD and other inflammatory diseases, since validated information on periodontal status is often lacking, while serum cohorts are available. The antibody-response to citrullinated  P.PAD in RA could be confirmed and evaluated in more detail. This antibody response was confined to ACPA+ RA and specific epitopes, where CPP5 was particularly interesting as antibodies associated with both ACPA+ RA and PD, supporting the hypothesis that PD/P. gingivalis may be causatively linked to the development of ACPA+ RA.


Disclosure:

N. Kharlamova,
None;

N. Sherina,
None;

A. M. Quirke,
None;

K. Eriksson,
None;

L. Israelsson,
None;

J. Potempa,
None;

P. Venables,
None;

T. Yucel-Lindberg,
None;

K. Lundberg,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antibodies-to-porphyromonas-gingivalis-as-an-etiological-clue-to-the-development-of-anti-citrullinated-protein-antibody-positive-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology